Pearl Therapeutics Receives $69,000,000 Series C Financing Round

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f850f32f-a55d-4ec7-9043-d6762dae0c23&Preview=1
Date
10/19/2010
Company Name
Pearl Therapeutics
Mailing Address
200 Saginaw Drive Redwood City, CA 94063
Company Description
Pearl Therapeutics is focused on developing a pipeline of novel and
superior products for chronic respiratory disorders, providing patients
with advanced therapeutic options in familiar and well accepted dosage
forms. The company has licensed advanced particle technology from Nektar
Therapeutics (Nasdaq: NKTR) for developing a series of products in selected
therapeutic fields.
Website
http://www.pearltherapeutics.com
Transaction Type
Venture Equity
Transaction Amount
$69,000,000
Transaction Round
Series C
Proceeds Purposes
The capital raised in this Series C financing will enable Pearl to complete the entire Phase 2b program for its lead product.
M&A Terms
Venture Investor
Vatera Healthcare Partners
Venture Investor
Clarus Ventures
Venture Investor
New Leaf Venture Partners
Venture Investor
5AM Ventures